North America

Latest move in Ericsson v Samsung shows how PTAB reforms are changing big-ticket licensing fights

The Korean tech giant has moved quickly to file a pair of IPRs against its rival’s patents but has so far not targeted any of those asserted in US district court

Latest move in Ericsson v Samsung shows how PTAB reforms are changing big-ticket licensing fights
Allergan’s Botox trade secrets win at the ITC win underlines its growing importance in life sciences IP disputes
26 Jan 2021

Allergan’s Botox trade secrets win at the ITC win underlines its growing importance in life sciences IP disputes

Victory for the US company and its Korean partner Medytox shows how Section 337 proceedings are becoming a vital enforcement tool for pharma and biotech rights owners

As Austin feels the benefits of "Texadus", the local IP market also sees a boost
25 Jan 2021

As Austin feels the benefits of "Texadus", the local IP market also sees a boost

With Big Tech flocking to the city and the rise of the Western District as a litigation hub, the state capital is firmly on the patent radar

Latest

View all
23 Jan 2021

Rebooting IP engagement with China need not mean giving up ground on key concerns

The patent world functions better when its two most powerful players have a constructive, though competitive, relationship Read more

22 Jan 2021

Qualcomm’s chip sales plunge in China underlines value of its licensing business

According to recent data, the company saw its share of the Chinese smartphone market shrink dramatically in 2020, making the multi-billion-dollar return from its patent portfolio even more important Read more

22 Jan 2021

The top patent prosecution firms in the US for 2020

Data shows that Oblon retained the number one spot but has lost some steam, while Fish & Richardson made big gains Read more

22 Jan 2021

Chinese lidar manufacturer paid $20 million upfront plus ongoing royalties to settle Velodyne dispute

Hesai Photonics Technology reveals monetary details of settlement, which also involves ongoing royalty payments through 2030 Read more

Designs

View all
4 Dec 2020

3M’s diversity pioneer on why data and collaboration are key to broadening the innovation pool

After seeing her work recognised by the IPO, the company's assistant chief IP counsel Sandra Nowak spoke with IAM on why some parts of the market are still playing catch-up Read more

21 Nov 2020

RCEP is a leap for China but a small step for IP

World’s largest trade pact is not a show-stopper when it comes to IP, but it will bring changes to ASEAN and clouds US ability to set regional agenda Read more

28 Oct 2020

Help us to identify the world's leading IP strategists

The research process for the IAM Strategy 300 2021 is now underway and we are inviting nominations as we decide who should be included Read more

24 Oct 2020

To educate lawyers who change the world, we cannot let this crisis go to waste

As the covid-19 pandemic continues to upend education in the US and beyond, there is an opportunity to create a new normal in how IP is taught, says Megan Carpenter, Dean of the Franklin Pierce School of Law Read more

Finance

View all
8 Jan 2021

South Korea's Intellectual Discovery is in the process of becoming a big league, mainstream NPE

A year after a major capital infusion and a change of leadership, the firm has notched some notable settlements in the US and laid the groundwork for new assertion campaigns Read more

12 Dec 2020

It’s time for investors to re-assess intangibles

A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models Read more

2 Nov 2020

Leaders of the world’s patent deals pack

The countdown of this year's IAM Market Makers - our annual ranking of the 40 most influential players in the global IP market - begins today with places 40 to 21 Read more

7 Oct 2020

Aon launches potentially game-changing IP financing initiative with $100 million loan to agritech company

“This is the first time you have had the financial industry and the insurance industry come together to create this much capital backed solely by IP,” says CEO Lee Read more

Frand/SEPS

View all
21 Jan 2021

Ericsson's fight with Samsung will end in a deal but the rise of China's courts adds a complex new dynamic

Both sides are looking for leverage in their complex global litigation but the speed of the court in Wuhan must concern the Swedish telco Read more

19 Jan 2021

VVC patents are setting the secondary market on fire

Why IP rights related to the latest video codec are this year’s must-have portfolio additions Read more

19 Jan 2021

After early FRAND litigation efforts in China, KPN targets Xiaomi and others in US courts

Expanded US litigation campaign targets some of the same mobile companies Dutch firm has pursued in China for years Read more

15 Jan 2021

New Fortress-backed NPE goes on patent attack against Apple, Dell and LG

Records show that plaintiff Neo Wireless was assigned a portfolio of wireless assets related to 4G and 5G in early 2020 Read more

Law & Policy

View all
21 Jan 2021

Why 2021 will be a pivotal year for life sciences patents in China

Despite radical reforms, pharma and biotech innovators still have unanswered questions about the country’s IP system Read more

20 Jan 2021

As he exits the USPTO, Iancu has his say on where policy priorities should lie

Outgoing agency head raises prospects of a national innovation and IP strategy, while also urging a greater focus on the SEP landscape Read more

13 Jan 2021

Qualcomm-backed advocacy group makes pitch to Biden on patent system in “distress”

With inauguration just days away a growing band of IP organisations are having their say on what direction patent policy should take over the next four years Read more

12 Jan 2021

Newly-passed Orange Book law leaves the big questions unanswered

Clearing up remaining uncertainties over FDA patent listings will be the subject of intense debate in the US over coming months Read more

Litigation

View all
21 Jan 2021

Ericsson's fight with Samsung will end in a deal but the rise of China's courts adds a complex new dynamic

Both sides are looking for leverage in their complex global litigation but the speed of the court in Wuhan must concern the Swedish telco Read more

21 Jan 2021

Why 2021 will be a pivotal year for life sciences patents in China

Despite radical reforms, pharma and biotech innovators still have unanswered questions about the country’s IP system Read more

20 Jan 2021

Japanese industrial giant goes on patent offensive with US lawsuit

Motor maker Nidec takes action to defend its huge market share in hard drive components Read more

19 Jan 2021

After early FRAND litigation efforts in China, KPN targets Xiaomi and others in US courts

Expanded US litigation campaign targets some of the same mobile companies Dutch firm has pursued in China for years Read more

Market Developments

View all
19 Jan 2021

After early FRAND litigation efforts in China, KPN targets Xiaomi and others in US courts

Expanded US litigation campaign targets some of the same mobile companies Dutch firm has pursued in China for years Read more

15 Jan 2021

Oppo’s patent focus: smaller deals, younger rights and future standards

Shanghai-based R&D firm Langbo inks its first patent sale to a major Chinese buyer after a pair of deals with foreign NPEs Read more

4 Jan 2021

The big IP stories you’ll be reading about in 2021

The IAM editorial team identifies what could be this year’s pivotal developments in the global IP market Read more

23 Dec 2020

North America’s biggest patent stories of 2020

From a potential sale of the BlackBerry portfolio to a record year for big damages awards its been a busy 12 months in the US and Canada Read more

Non-Practising Entities

View all
15 Jan 2021

New Fortress-backed NPE goes on patent attack against Apple, Dell and LG

Records show that plaintiff Neo Wireless was assigned a portfolio of wireless assets related to 4G and 5G in early 2020 Read more

14 Jan 2021

Deal with RPX a huge win for IV - and other takeaways from a licensing blockbuster

After we exclusively broke the news of the big ticket transaction we look at the key points to have emerged from the agreement Read more

12 Jan 2021

Samsung and WiLAN patent transfers point to more semiconductor deal activity

Two separate assignments have seen the Korean tech giant and the NPE acquire assets from IBM and Mediatek Read more

11 Jan 2021

Exclusive: RPX and Intellectual Ventures ink landmark licensing deal

IV’s Arvin Patel helps drive transaction just months after joining from TiVo; while RPX CEO McCurdy hails comprehensive licence in transaction valued in low nine figures Read more

Patent Pools

View all
19 Jan 2021

VVC patents are setting the secondary market on fire

Why IP rights related to the latest video codec are this year’s must-have portfolio additions Read more

18 Jan 2021

Elite US universities come together to break technology licensing “logjam”

A group of 15 leading institutions, led by Columbia, is hoping that a new pool will unlock more value from their patents and help change the mindset of Big Tech Read more

15 Jan 2021

Oppo’s patent focus: smaller deals, younger rights and future standards

Shanghai-based R&D firm Langbo inks its first patent sale to a major Chinese buyer after a pair of deals with foreign NPEs Read more

15 Dec 2020

HEVC licensing platform Velos Media makes a change at the top

New head Greg Weiss warns of a more fractured video licensing landscape if stakeholders don’t get VVC process right Read more

Patents Law

View all
21 Jan 2021

Ericsson's fight with Samsung will end in a deal but the rise of China's courts adds a complex new dynamic

Both sides are looking for leverage in their complex global litigation but the speed of the court in Wuhan must concern the Swedish telco Read more

21 Jan 2021

Why 2021 will be a pivotal year for life sciences patents in China

Despite radical reforms, pharma and biotech innovators still have unanswered questions about the country’s IP system Read more

20 Jan 2021

As he exits the USPTO, Iancu has his say on where policy priorities should lie

Outgoing agency head raises prospects of a national innovation and IP strategy, while also urging a greater focus on the SEP landscape Read more

20 Jan 2021

Japanese industrial giant goes on patent offensive with US lawsuit

Motor maker Nidec takes action to defend its huge market share in hard drive components Read more

Strategy

View all
19 Jan 2021

After early FRAND litigation efforts in China, KPN targets Xiaomi and others in US courts

Expanded US litigation campaign targets some of the same mobile companies Dutch firm has pursued in China for years Read more

15 Jan 2021

Oppo’s patent focus: smaller deals, younger rights and future standards

Shanghai-based R&D firm Langbo inks its first patent sale to a major Chinese buyer after a pair of deals with foreign NPEs Read more

6 Jan 2021

Inside Samsung's Wuhan anti-suit injunction against Ericsson

Text of China's latest big FRAND decision is revealed to mixed reactions as dispute between the two companies escalates Read more

4 Jan 2021

The big IP stories you’ll be reading about in 2021

The IAM editorial team identifies what could be this year’s pivotal developments in the global IP market Read more

Technology Licensing

View all
21 Jan 2021

Ericsson's fight with Samsung will end in a deal but the rise of China's courts adds a complex new dynamic

Both sides are looking for leverage in their complex global litigation but the speed of the court in Wuhan must concern the Swedish telco Read more

19 Jan 2021

VVC patents are setting the secondary market on fire

Why IP rights related to the latest video codec are this year’s must-have portfolio additions Read more

19 Jan 2021

After early FRAND litigation efforts in China, KPN targets Xiaomi and others in US courts

Expanded US litigation campaign targets some of the same mobile companies Dutch firm has pursued in China for years Read more

18 Jan 2021

Elite US universities come together to break technology licensing “logjam”

A group of 15 leading institutions, led by Columbia, is hoping that a new pool will unlock more value from their patents and help change the mindset of Big Tech Read more

Trade Secrets

View all
7 Jan 2021

Surprise change to FDA Purple Book creates risks and opportunities for biosimilar producers

A US patent transparency amendment has mixed implications for the strategies pursued by biologics copycat producers Read more

22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

12 Dec 2020

It’s time for investors to re-assess intangibles

A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models Read more

4 Dec 2020

3M’s diversity pioneer on why data and collaboration are key to broadening the innovation pool

After seeing her work recognised by the IPO, the company's assistant chief IP counsel Sandra Nowak spoke with IAM on why some parts of the market are still playing catch-up Read more

Valuation

View all
22 Dec 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies. Read more

16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

12 Dec 2020

It’s time for investors to re-assess intangibles

A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models Read more

3 Dec 2020

New patent politics put US public-private partnerships under threat, says BIO’s IP chief

In an exclusive interview, Hans Sauer talks of concerns over a shift in federal strategy and argues that government research funding should not be seen as a commercial investment Read more

Find an expert